Non-Compartmental Analysis (NCA)
Comprehensive PK characterization, bioequivalence assessment, and exposure analysis supporting IND through NDA
Pharmacology & Modeling (PK/PD)
Advanced PK/PD Expertise Driving Optimal Dosing from First-in-Human to Market
Get in Touch 
What we can do
Population PK/PD Modeling
Robust covariate analysis, dose optimization, and exposure-response relationships for labeling claims
PBPK Modeling Excellence
DDI prediction, pediatric extrapolation, and organ impairment assessment enabling accelerated development
Model-Informed Drug Development
Strategic integration supporting dose selection, trial design optimization, and regulatory interactions
Advanced PK/PD Expertise Driving Optimal Dosing from First-in-Human to Market
Model-informed drug development from first-in-human to approval, leveraging advanced pharmacometric analytics to optimize dosing strategies, maximize efficacy, minimize risk and accelerate development.
What we offer
Early Phase
- Dose prediction & escalation strategy
- Safety assessment & PK analysis plan
Development Phase
- Population PK/PD models & reports
- Dose optimization recommendations
Late Stage
- Integrated analyses for submission
- Special population guidance
Regulatory Package
- Regulatory-ready documentation
- Complete model packages
Service category 1Clinical Pharmacology Studies
- First-in-Human Dose Selection
- Bioequivalence & Biosimilarity
- Food Effect & Drug Interactions
- PK Characterization & Analysis
Service category 2Dose Optimization & Modeling
- Population Modeling for Optimal Dosing
- Exposure-Response Relationships
- Dose Adjustment for Special Populations
- Safety Margin Assessment
Service category 3Special Population Strategies
- Pediatric Dose Prediction
- Renal/Hepatic Impairment Dosing
- Elderly & Vulnerable Populations
- Pharmacogenomics Impact
Service category 4Regulatory & Strategic Support
- Clinical Pharmacology Packages
- Scientific Advice
- Labeling Strategy & Claims
- Model-Informed Development Plans
How We Engage
A streamlined 4-step approach to clinical excellence.
1
Study Design Input
1-2 weeks
- Protocol PK/PD review
- Sampling strategy optimization
- Bioanalytical coordination
2
Data Analysis & Modeling
3-6 weeks
- NCA execution
- PopPK/PD development
- Exposure-response characterization
3
Simulation & Optimization
2-3 weeks
- Dose selection support
- Trial simulation
- Virtual patient populations
4
Regulatory Deliverables
2-4 weeks
- PK/PD reports
- Clinical pharmacology sections
- Regulatory response support
Ready to optimize your clinical trial?
Accelerating Drug Development with Data-Driven Biometrics & Clinical Intelligence.
Submit RFP Pharmacology & Modeling (PK/PD)
Advanced PK/PD Expertise Driving Optimal Dosing from First-in-Human to Market
Get in Touch What we can do
Non-Compartmental Analysis (NCA)
Comprehensive PK characterization, bioequivalence assessment, and exposure analysis supporting IND through NDA
Population PK/PD Modeling
Robust covariate analysis, dose optimization, and exposure-response relationships for labeling claims
PBPK Modeling Excellence
DDI prediction, pediatric extrapolation, and organ impairment assessment enabling accelerated development
Model-Informed Drug Development
Strategic integration supporting dose selection, trial design optimization, and regulatory interactions
Advanced PK/PD Expertise Driving Optimal Dosing from First-in-Human to Market
Model-informed drug development from first-in-human to approval, leveraging advanced pharmacometric analytics to optimize dosing strategies, maximize efficacy, minimize risk and accelerate development.
What we offer
Early Phase
- Dose prediction & escalation strategy
- Safety assessment & PK analysis plan
Development Phase
- Population PK/PD models & reports
- Dose optimization recommendations
Late Stage
- Integrated analyses for submission
- Special population guidance
Regulatory Package
- Regulatory-ready documentation
- Complete model packages
Service category 1
Clinical Pharmacology Studies
- First-in-Human Dose Selection
- Bioequivalence & Biosimilarity
- Food Effect & Drug Interactions
- PK Characterization & Analysis
Service category 2
Dose Optimization & Modeling
- Population Modeling for Optimal Dosing
- Exposure-Response Relationships
- Dose Adjustment for Special Populations
- Safety Margin Assessment
Service category 3
Special Population Strategies
- Pediatric Dose Prediction
- Renal/Hepatic Impairment Dosing
- Elderly & Vulnerable Populations
- Pharmacogenomics Impact
Service category 4
Regulatory & Strategic Support
- Clinical Pharmacology Packages
- Scientific Advice
- Labeling Strategy & Claims
- Model-Informed Development Plans
How We Engage
A streamlined 4-step approach to clinical excellence.
1
Study Design Input
1-2 weeks
- Protocol PK/PD review
- Sampling strategy optimization
- Bioanalytical coordination
2
Data Analysis & Modeling
3-6 weeks
- NCA execution
- PopPK/PD development
- Exposure-response characterization
3
Simulation & Optimization
2-3 weeks
- Dose selection support
- Trial simulation
- Virtual patient populations
4
Regulatory Deliverables
2-4 weeks
- PK/PD reports
- Clinical pharmacology sections
- Regulatory response support
Ready to optimize your clinical trial?
Accelerating Drug Development with Data-Driven Biometrics & Clinical Intelligence.
Submit RFP